Journal
BIOMATERIALS
Volume 32, Issue 30, Pages 7711-7720Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2011.06.066
Keywords
Mesoporous silica; Nanoparticle; Controlled drug release; Multi-drug delivery; One-pot self-assembly; Multi-drug resistance
Funding
- NSFC [50823007, 50972154, 51072212]
- National Basic Research Program of China [2011CB707905, 2010CB934000]
- Science and Technology Commission of Shanghai [10430712800]
- CASKJCX [KJCX2-YW-210]
- Science Foundation for Youth Scholar of State Key Laboratory of High Performance Ceramics and Superfine Microstructures [SKL201001]
Ask authors/readers for more resources
A type of pH-responsive nano multi-drug delivery systems (nano-MDDSs) with uniform particle size (100 +/- 13 nm) and excellent monodispersity was developed by in situ co-self-assembly among water-insoluble anti-cancer drug (doxorubicin, DOX), surfactant micelles (CTAB) as chemosensitiver and silicon species forming drugs/surfactant micelles-co-loaded mesoporous silica nanoparticles (drugs@micelles@MSNs or DOX@CTAB@MSNs) via a micelles-MSNs self-assembly mechanism. The nano-MDDS DOX@CTAB@MSNs had a highly precise pH-responsive drug release behavior both in vitro and in vivo, and exhibited high drug efficiencies against drug-resistant MCF-7/ADR cells as well as drug-sensitive MCF-7 cells by the MSNs-mediated transmembrane delivery, the sustained drug release and the high anti-cancer and multi-drug resistance (MDR)-overcoming efficiencies. The MDR-overcoming mechanism was proved to be a synergistic cell cycle arrest/apoptosis-inducing effect resulted from the chemosensitization of the surfactant CTAB. These results demonstrated a very promising nano-MDDS for the pH-responsive controlled drug release and the cancer MDR overcoming. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available